Year-end Sale % OFF 
Abstract
Pulmonary surfactant preparations extracted from natural sources have been used to treat millions of newborn babies with respiratory distress syndrome (RDS) and can possibly also be used to treat other lung diseases. Due to costly production and limited supply of animal-derived surfactants, synthetic alternatives are attractive. The water insolubility and aggregation-prone nature of the proteins present in animal-derived surfactant preparations have complicated development of artificial surfactant. A non-aggregating analog of lung surfactant protein C, SP-C33Leu is used in synthetic surfactant and we recently described an efficient method to produce rSP-C33Leu in bacteria. Here rSP-C33Leu obtained by salt precipitation of bacterial extracts was purified by two-step liquid gel chromatography and analyzed using mass spectrometry and RP-HPLC, showing that it is void of modifications and adducts. Premature New Zealand White rabbit fetuses instilled with 200mg/kg of 2% of rSP-C33Leu in phospholipids and ventilated with a positive end expiratory pressure showed increased tidal volumes and lung gas volumes compared to animals treated with phospholipids only. This shows that rSP-C33Leu can be purified from bacterial lipids and that rSP-C33Leu surfactant is active against experimental RDS.
Highlights
Pulmonary surfactant lines the terminal air spaces and reduces the surface tension of the alveolar liquid layer, which is necessary for pulmonary compliance and alveolar patency at endexpiration [1]
Two potential problems with salt precipitation followed by solubilisation in organic solvents are that various amounts of NaCl will be found in the organic extract and that lipids of different polarity as well as many undefined components will copurify with the lipophilic peptide rSP-C33Leu
Material eluting in fractions corresponding to 4 and 5 in Fig 2B were used for further analyses and for surfactant preparation since most of the peptide was found in fraction 5, and the smaller size and higher hydrophobicity of lipid contaminants make them elute later from the Lipidex column
Summary
Pulmonary surfactant lines the terminal air spaces and reduces the surface tension of the alveolar liquid layer, which is necessary for pulmonary compliance and alveolar patency at endexpiration [1]. The main component of lung surfactant is phospholipids. Phosphatidylcholines (PC) constitute 60–70% of surfactant phospholipids and anionic phospholipids, mainly phosphatidylglycerol (PG) constitutes 8–15%.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
